title: Efficacy of different doses of atorvastatin treatment on serum levels of 8-hydroxy-guanin (8-OHdG) and cardiac function in patients with ischemic cardiomyopathy.
abstract: OBJECTIVE
  To compare the efficacy of 40 mg and l0 mg atorvastatin on serum levels of 8-Hydroxy-Guanin (8-OHdG) and the cardiac function in patients with ischemic cardiomyopathy (ICM).
  
  
  METHODS
  One hundred twenty three hospitalized ICM patients and 120 healthy controls were included in this study. All subjects were randomly divided into two groups: 10 mg/d atorvastatin group (n=62) and 40 mg/d atorvastatin group (n=61). Serum levels of C-reactive protein (CRP), creatine kinase, glutamic-pyruvic transaminase, lipids and B-type natriuretic peptide (BNP) were tested in all subjects both at the initial phase and the terminal phase of this study. Adverse drug reaction events were recorded in this study. Echocardiographic method was applied to compare the cardiac function before and after treatment in the double blind study. Serum 8-OHdG levels were tested by enzyme-linked immunosorbent assay (ELISA) before and after treatment, and the results in atorvastatin treatment groups were compared with the healthy controls.
  
  
  RESULTS
  Serum 8-OHdG levels in ICM patients were significantly higher than that in normal control groups (p<0.05). There was significant difference of Serum 8-OHdG levels in 40 mg/d atorvastatin group (p<0.05), but was no significant difference in 10 mg/d atorvastatin group before and after the treatment. The 8-OHdG level in 40 mg/d atorvastatin group was significantly lower than that in 10 mg/d atorvastatin group before the treatment as well as after the treatment (p<0.05). The systolic and diastolic function improved significantly in 40 mg/d atorvastatin group before and after treatment, as well as in comparison with 10 mg/d atorvastatin group (p<0.05).
  
  
  CONCLUSIONS
  Serum 8-OHdG possibly plays an important role in the pathogenesis of ICM. Atorvastatin is safe and effective in ICM treatment; furthermore atorvastatin which also has independent lipid lowering effect, is significantly better in the dose of 40 mg/day.
authors: Yu Jin, Department of Cardiology,Wuhan General Hospital of Guangzhou Military Command, Wuhan 430070, Hubei Province, China.
authors: Yu
authors: Y
authors: Jin
authors: Chunguang Qiu, Department of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
authors: Chunguang
authors: C
authors: Qiu
authors: Qiangsun Zheng, Department of Cardiology, Tangdu Hospital of the Fourth Military Medical University, Xi'an 700038, Shanxi Province, China.
authors: Qiangsun
authors: Q
authors: Zheng
authors: Ling Liu, Third Department of Cardiology, Xinxiang Central Hospital, Xinxiang 453000, Henan Province, China.
authors: Ling
authors: L
authors: Liu
authors: Zhiqiang Liu, Third Department of Cardiology, Xinxiang Central Hospital, Xinxiang 453000, Henan Province, China.
authors: Zhiqiang
authors: Z
authors: Liu
authors: Yi Wang, Third Department of Cardiology, Xinxiang Central Hospital, Xinxiang 453000, Henan Province, China.
authors: Yi
authors: Y
authors: Wang
keywords: 8-Hydroxrguanin; Atorvastatin; DNA damage; Ischemic cardiomyopathy; Oxidative stress